Search - tctmd.com

Displaying 21 - 40 of 355

Sort: Relevancy | Date

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

BVS at the Cusp of Complete Bioresorption: MLD and Vasomotion at 3-years in Absorb and Xience from the ABSORB II trial

Presenter: Stephen G. Ellis, Corrado Tamburino, Patrick W. Serruys

October 31, 2016

Presentation TCT 2016

TCT 70: Final 5 Year Results from the COMPARE II Trial: Comparison Between the Durable Polymer Coated Everolimus-Eluting Xience/Promus Stent and the Biodegradable Polymer Coated Biolimus-Eluting Nobori Stent in All-Comer Population

Presenter: Giuseppe De Luca, Christoph A. Kaiser, Pieter C. Smits

October 31, 2016

News Conference News TCT 2016

EXCEL 和 NOBLE：左主干 PCI/CABG 的选择结果相悖

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

Michael O'Riordan

October 31, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Xience Cobalt Chromium Fluoropolymer-Based Everolimus-Eluting Stents

Presenter: Dean J. Kereiakes, Pieter C. Smits, Tullio Palmerini

October 30, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

News Conference News ESC 2016

NIPPON: With Nobori Stent, 6 Months of DAPT as Safe and Effective as 18 Months

Michael O'Riordan

August 28, 2016

News Features

The Bioresorbable Stent Story So Far: What Promise? What Price?

Michael O'Riordan

August 17, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

News Daily News

Según un Meta Análisis en Red el Riesgo de Trombosis del Andamiaje con el BVS Absorb es Mayor que con Otros Stents

Michael O'Riordan

June 06, 2016

News Daily News

Higher Scaffold Thrombosis Risk With Absorb BVS vs a Wide Range of Stents: Network Meta-Analysis

Michael O'Riordan

June 06, 2016

News Daily News

Absorb BVS 与多种支架相比支架血栓形成风险更高：网络 Meta 分析

Michael O'Riordan

June 06, 2016

News Daily News

糖尿病患者（即使需要胰岛素）中依维莫司支架优于紫杉醇支架：TUXEDO 分析

Michael O'Riordan

April 25, 2016

News Daily News

Everolimus Stent Better Than Paclitaxel Stent in Diabetic Patients, Even Those Requiring Insulin: TUXEDO Analysis

Michael O'Riordan

April 25, 2016

News Daily News

Análisis del TUXEDO: Los Stents de Everolimus son Mejores que los de Paclitaxel en Pacientes Diabéticos, Incluso en Insulinodependientes

Michael O'Riordan

April 25, 2016

News Daily News

AVB Absorb: Seguridad, Eficacia y Trombosis del Stent a Estudio en 2 Nuevos Análisis

Michael O'Riordan

March 30, 2016

News Daily News

Absorb BVS: Safety, Efficacy, and Stent Thrombosis Tackled in Two New Analyses

Michael O'Riordan

March 30, 2016

News Daily News

Absorb BVS：两项新研究解决了安全性、有效性和支架血栓问题

Michael O'Riordan

March 30, 2016

Advertisement

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

BVS at the Cusp of Complete Bioresorption: MLD and Vasomotion at 3-years in Absorb and Xience from the ABSORB II trial

TCT 70: Final 5 Year Results from the COMPARE II Trial: Comparison Between the Durable Polymer Coated Everolimus-Eluting Xience/Promus Stent and the Biodegradable Polymer Coated Biolimus-Eluting Nobori Stent in All-Comer Population

EXCEL 和 NOBLE：左主干 PCI/CABG 的选择结果相悖

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

Stent Design and Comprehensive Data Review: Xience Cobalt Chromium Fluoropolymer-Based Everolimus-Eluting Stents

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

NIPPON: With Nobori Stent, 6 Months of DAPT as Safe and Effective as 18 Months

The Bioresorbable Stent Story So Far: What Promise? What Price?

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Según un Meta Análisis en Red el Riesgo de Trombosis del Andamiaje con el BVS Absorb es Mayor que con Otros Stents

Higher Scaffold Thrombosis Risk With Absorb BVS vs a Wide Range of Stents: Network Meta-Analysis

Absorb BVS 与多种支架相比支架血栓形成风险更高：网络 Meta 分析

糖尿病患者（即使需要胰岛素）中依维莫司支架优于紫杉醇支架：TUXEDO 分析

Everolimus Stent Better Than Paclitaxel Stent in Diabetic Patients, Even Those Requiring Insulin: TUXEDO Analysis

Análisis del TUXEDO: Los Stents de Everolimus son Mejores que los de Paclitaxel en Pacientes Diabéticos, Incluso en Insulinodependientes

AVB Absorb: Seguridad, Eficacia y Trombosis del Stent a Estudio en 2 Nuevos Análisis

Absorb BVS: Safety, Efficacy, and Stent Thrombosis Tackled in Two New Analyses

Absorb BVS：两项新研究解决了安全性、有效性和支架血栓问题

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content